PPMD Community

Conference Call 48-Week Results From the Phase IIb exon 51 skip DMD Study

Sarepta Therapeutics Announces Conference Call and Webcast on Wednesday, October 3, 2012, to Discuss 48-Week Results From the Phase IIb DMD Study

Oct 02, 2012 (Marketwire via COMTEX) --Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, announced today it will hold a conference call at 8:00 a.m. EDT (5:00 a.m. PDT) on Wednesday, October 3, 2012 to discuss 48-week results from its Phase IIb study evaluating eteplirsen for the treatment of Duchenne muscular dystrophy (DMD). 

The conference call may be accessed by dialing 866.356.3093 begin_of_the_skype_highlighting FREE 866.356.3093 end_of_the_skype_highlighting for domestic callers and 617.597.5381 begin_of_the_skype_highlighting FREE 617.597.5381 end_of_the_skype_highlighting for international callers. The passcode for the call is 93880948. Please specify to the operator that you would like to join the "Sarepta Therapeutics 48-Week Results Call." The conference call will be webcast live under the events section of Sarepta's website at www.sareptatherapeutics.com and will be archived there following the call for 90 days. Please connect to Sarepta's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.

About Sarepta Therapeutics

Sarepta Therapeutics is focused on developing first-in-class RNA-based therapeutics to improve and save the lives of people affected by serious and life-threatening rare and infectious diseases. The Company's diverse pipeline includes its lead program eteplirsen, for Duchenne muscular dystrophy, as well as potential treatments for some of the world's most lethal infectious diseases. Sarepta aims to build a leading, independent biotech company dedicated to translating its RNA-based science into transformational therapeutics for patients who face significant unmet medical needs. For more information, please visit us at www.sareptatherapeutics.com.

Sarepta Investor and Media Contact:         Erin Cox         425.354.5140 begin_of_the_skype_highlighting FREE 425.354.5140 end_of_the_skype_highlighting         Email Contact 

Views: 1168

Reply to This

Replies to This Discussion

Share price dropped 9% yesterday. I hope this isn't bad news? I hope it was caused by institutions offloading shares to try and reduce the price and go in again to buy big today?..although I thought that was illlegal?.......

it's pretty good!!!!!!!!!!!!!!!!!!!!!!!!!!!!

Every parent should listen to the conference call conducted this morning by Sarepta: http://investorrelations.avibio.com/phoenix.zhtml?c=64231&p=iro...

It is archived along with slides.

Nothing short of fantastic results. Prayers answered.

BRING ON THE CAPITALISTS

THERE IS GOLD IN THEM THAR OLIGOS

Sarepta Therapeutics, Inc. (SRPT)

-NasdaqGM

39.52 Up 24.53(163.64%) 12:33PM EDT - Nasdaq Real Time Price

Sarepta CEO will be on CNBC Mad Money tonight Oct. 03 at 6pm and 11pm

Hi everybody

my son has been diagnose from DMD, he has a point mutation in exon 34, a deletion of a nucleotide c 4841. I would like to know if somebody has also the same kind of mutation, and what is coming for patients with this kind of mutations?

kind regards

Gonzalo

Approval please! Approval!!!

What I cannot stop thinking about ... not the stock PPS, the conditions for FDA approval, the financial partnerships that may develop ...

What I cannot stop thinking about are a handful of young men who are PUTTING AWAY THEIR CHAIRS.

2012 is Year 0

 

Hi, wondering if anyone could shed any light on a couple of things. 

My son has an exon 43 deletion, which would be helped by the current Prosensa PRO044 trial drug getting tested at the moment. 

1. Is it the same method of exon skipping that both Sarepta & Prosensa are using?

2. If Sarepta 'win' the race to produce exon skipping for the market (& Prosensa slow down their research), have they got any plans for exon skipping which would help with 43 deletion? (I know they are already doing 51 & 50)

Thanks, if anyone can enlighten me. 

They are NOT the same chemistry, no. They are the same basic "technique" to use sufficiently vague term. They are both trying to allow the body to create partial dystrophin through the exon-skip, so the effects of each should be similar if not identical for the same amount of dystrophin produced.

But Prosensa uses PPMO chemistry while Sarepta uses PMO. The exact differences are beyond my understanding, but there are significant differences.

It SEEMS from GSK trials that PPMO works faster in producting first dystrophin, by matter of weeks. Sarepta is slower to show dystrophin production, but does kick in after at least 36 weeks, and SEEMS to have better safety profile so far.

DISCLAIMER - I am obsessed parent only, not medical professional

like!

David said:

They are NOT the same chemistry, no. They are the same basic "technique" to use sufficiently vague term. They are both trying to allow the body to create partial dystrophin through the exon-skip, so the effects of each should be similar if not identical for the same amount of dystrophin produced.

But Prosensa uses PPMO chemistry while Sarepta uses PMO. The exact differences are beyond my understanding, but there are significant differences.

It SEEMS from GSK trials that PPMO works faster in producting first dystrophin, by matter of weeks. Sarepta is slower to show dystrophin production, but does kick in after at least 36 weeks, and SEEMS to have better safety profile so far.

DISCLAIMER - I am obsessed parent only, not medical professional

Reply to Discussion

RSS

© 2014   Created by PPMD.

Badges  |  Report an Issue  |  Privacy Policy  |  Terms of Service